Last reviewed · How we verify
NCT03951519: WATER
Effect of Oral Water on the Quality of Volume Expansion in Resuscitation Patients
NA trial testing oral administration of water in Intubated-ventilated Patients in the Intensive Care Unit in 50 participants. Completed in 30 January 2020.
30 January 2020
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 24 May 2019 |
| Primary completion | 30 January 2020 |
| Estimated completion | 30 January 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- oral administration of water
- administration of saline solution
Conditions studied
- Intubated-ventilated Patients in the Intensive Care Unit — all drugs for Intubated-ventilated Patients in the Intensive Care Unit →
Sponsor
Centre Hospitalier Universitaire Dijon
Who can join
18 and older, any sex, with Intubated-ventilated Patients in the Intensive Care Unit. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In ICU and operating theatre, fluid expansion is the main hemodynamic therapeutic. The objective of fluid expansion is to increase cardiac output thus arterial oxygen delivery to match patient's oxygen consumption. To date, it has been shown that all fluid expansion solutions may have side effects (hydro-electrolytic disorder, renal failure, hydro-sodium overload, etc.) that may limit their use. Human digestive system physiologically ensures the absorption of oral water and hydration of the human body. Water is quickly absorbed by the digestive tract with a peak between 15 and 20 minutes. It has demonstrated that oral water remains the best hydration solution that have an effect on plasma volume expansion and cardiovascular system during exercise. While the cardiovascular effect of fluid expansion by saline serum is well known (venous return, preload and cardiac output), that of oral water vary in the literature depending on the physiological state of the patient and the clinical state. Oral water can change cardiac output and blood pressure through various physiological effects: increased blood volume, recruitment of splanchnic blood volume, and peripheral vasoconstriction. Usually, ICU patients have feeding through nasogastric tube. To date, no study has studied the effect of a given amount of enteral cardiovascular system in ICU patients. The objective of this study is to describe the effect of oral water administration on the cardiovascular system of patients during the optimization and/or hemodynamic stabilization phase. The comparison of groups (water/ physiological saline) would allow us: (1) to describe the cardiovascular effects of water in the resuscitation patient, (2) to compare these cardiovascular effects with those of saline solution, (3) to have the data to design further study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
ESICM LIVES 2020.
· 2020 · cited 13× · PMID 33313986 · DOI 10.1186/s40635-020-00354-8 -
Oral Water Has Cardiovascular Effects Up to 60 min in Shock Patients.
Guinot PG, Nguyen M, Duclos V, Berthoud V, et al · · 2021 · cited 1× · PMID 34988132 · DOI 10.3389/fcvm.2021.803979
Verify or expand the search:
- PubMed search for NCT03951519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire Dijon trials
Trials by the same sponsor.
- NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
- NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
- NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
- NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
- NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03951519 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing